Switching from innovator to biosimilar (subsequent entry) Infliximab a review of the clinical effectiveness, cost-effectiveness, and guidelines
The availability of biosimilar infliximab (INX) has been postulated to offer cost savings compared to innovator INX, which could lead to patients being switched between products. The purpose of this report is to summarize the comparative clinical and cost effectiveness of switching from innovator to...
| Corporate Authors: | , |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
[Ottowa, Ont.]
CADTH Rapid Response Service
26 February 2015, 2015
|
| Series: | Rapid response report: summary with critical appraisal
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The availability of biosimilar infliximab (INX) has been postulated to offer cost savings compared to innovator INX, which could lead to patients being switched between products. The purpose of this report is to summarize the comparative clinical and cost effectiveness of switching from innovator to biosimilar INX compared to continued use of innovator INX over a broad range of indications |
|---|---|
| Physical Description: | 1 PDF file (25 pages) illustrations |